title: Changes in left ventricular diastolic function of asymptomatic hereditary hemochromatosis subjects during five years of follow-up.
abstract: We have previously reported that left ventricular (LV) diastolic function in those with cardiac asymptomatic hereditary hemochromatosis (HH) is similar to that of volunteer control (VC) subjects, despite a presence of augmented left atrial contractile function. However, concern still exists that those with HH might gradually develop LV diastolic dysfunction despite receiving conventional phlebotomy treatment. To address this concern, we prospectively monitored the LV diastolic function of those with HH and VCs during a 5-year period. A total of 14 subjects with newly diagnosed HH (age 51 ± 12 years, 4 women, group A), 20 with chronic HH (age 51 ± 9 years, 7 women, group B), and 18 VCs (age 50 ± 8 years, 6 women, group C) successfully completed both the baseline evaluation of LV diastolic function, including tissue Doppler imaging, strain rate analysis with color-coded tissue Doppler, and the same studies repeated at 5 years of follow-up. All those with HH were New York Heart Association functional class I, were positive for the C282Y homozygote, and received conventional phlebotomy therapy. No VC had HH genetic mutations. The measures of LV diastolic function were comparable among the groups at 5 years of follow-up by analysis of variance. The echocardiographic measures of active left atrial contraction tended to decrease in the HH groups at 5 years of follow-up from baseline. In conclusion, LV diastolic function does not significantly deteriorate statistically during a 5-year period in subjects with cardiac asymptomatic HH after conventional phlebotomy treatment, regardless of their treatment history.
authors.affiliation: Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA. shizukya@uc.edu
authors.forename: Yukitaka
authors.initials: Y
authors.lastname: Shizukuda
authors.forename: Dorothy J
authors.initials: DJ
authors.lastname: Tripodi
authors.forename: Vandana
authors.initials: V
authors.lastname: Sachdev
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Brenneman
authors.forename: Stanislav
authors.initials: S
authors.lastname: Sidenko
authors.forename: Marilyn
authors.initials: M
authors.lastname: St Peter
authors.forename: Charles D
authors.initials: CD
authors.lastname: Bolan
authors.forename: Yu Ying
authors.initials: YY
authors.lastname: Yau
authors.forename: Susan F
authors.initials: SF
authors.lastname: Leitman
authors.forename: Myron A
authors.initials: MA
authors.lastname: Waclawiw
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Rosing
mesh_terms: D003971:Diastole; D005260:Female; D005500:Follow-Up Studies; D006432:Hemochromatosis / Q000235:genetics* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D016277:Ventricular Function, Left